Literature DB >> 22933060

Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.

Tatiana Popova1, Elodie Manié, Guillaume Rieunier, Virginie Caux-Moncoutier, Carole Tirapo, Thierry Dubois, Olivier Delattre, Brigitte Sigal-Zafrani, Marc Bollet, Michel Longy, Claude Houdayer, Xavier Sastre-Garau, Anne Vincent-Salomon, Dominique Stoppa-Lyonnet, Marc-Henri Stern.   

Abstract

BRCA1 inactivation is a frequent event in basal-like breast carcinomas (BLC). However, BRCA1 can be inactivated by multiple mechanisms and determining its status is not a trivial issue. As an alternate approach, we profiled 65 BLC cases using single-nucleotide polymorphism arrays to define a signature of BRCA1-associated genomic instability. Large-scale state transitions (LST), defined as chromosomal break between adjacent regions of at least 10 Mb, were found to be a robust indicator of BRCA1 status in this setting. Two major ploidy-specific cutoffs in LST distributions were sufficient to distinguish highly rearranged BLCs with 85% of proven BRCA1-inactivated cases from less rearranged BLCs devoid of proven BRCA1-inactivated cases. The genomic signature we defined was validated in a second independent series of 55 primary BLC cases and 17 BLC-derived tumor cell lines. High numbers of LSTs resembling BRCA1-inactivated BLC were observed in 4 primary BLC cases and 2 BLC cell lines that harbored BRCA2 mutations. Overall, the genomic signature we defined predicted BRCA1/2 inactivation in BLCs with 100% sensitivity and 90% specificity (97% accuracy). This assay may ease the challenge of selecting patients for genetic testing or recruitment to clinical trials of novel emerging therapies that target DNA repair deficiencies in cancer. ©2012 AACR.

Entities:  

Mesh:

Year:  2012        PMID: 22933060     DOI: 10.1158/0008-5472.CAN-12-1470

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  216 in total

1.  Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast.

Authors:  Francisco Beca; Simon S K Lee; Fresia Pareja; Arnaud Da Cruz Paula; Pier Selenica; Lorenzo Ferrando; Rodrigo Gularte-Mérida; Hannah Y Wen; Hong Zhang; Elena Guerini-Rocco; Emad A Rakha; Britta Weigelt; Jorge S Reis-Filho
Journal:  Histopathology       Date:  2019-10-13       Impact factor: 5.087

2.  The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.

Authors:  Charlotte K Y Ng; Salvatore Piscuoglio; Felipe C Geyer; Kathleen A Burke; Fresia Pareja; Carey A Eberle; Raymond S Lim; Rachael Natrajan; Nadeem Riaz; Odette Mariani; Larry Norton; Anne Vincent-Salomon; Y Hannah Wen; Britta Weigelt; Jorge S Reis-Filho
Journal:  Clin Cancer Res       Date:  2017-02-02       Impact factor: 12.531

Review 3.  Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.

Authors:  Priyanka Sharma
Journal:  Curr Treat Options Oncol       Date:  2018-04-14

4.  TIPIN depletion leads to apoptosis in breast cancer cells.

Authors:  Céline Baldeyron; Amélie Brisson; Bruno Tesson; Fariba Némati; Stéphane Koundrioukoff; Elie Saliba; Leanne De Koning; Elise Martel; Mengliang Ye; Guillem Rigaill; Didier Meseure; André Nicolas; David Gentien; Didier Decaudin; Michelle Debatisse; Stéphane Depil; Francisco Cruzalegui; Alain Pierré; Sergio Roman-Roman; Gordon C Tucker; Thierry Dubois
Journal:  Mol Oncol       Date:  2015-05-09       Impact factor: 6.603

5.  TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

Authors:  Steven J Isakoff; Erica L Mayer; Lei He; Tiffany A Traina; Lisa A Carey; Karen J Krag; Hope S Rugo; Minetta C Liu; Vered Stearns; Steven E Come; Kirsten M Timms; Anne-Renee Hartman; Darrel R Borger; Dianne M Finkelstein; Judy E Garber; Paula D Ryan; Eric P Winer; Paul E Goss; Leif W Ellisen
Journal:  J Clin Oncol       Date:  2015-04-06       Impact factor: 44.544

6.  Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.

Authors:  Melinda L Telli; Kristin C Jensen; Shaveta Vinayak; Allison W Kurian; Jafi A Lipson; Patrick J Flaherty; Kirsten Timms; Victor Abkevich; Elizabeth A Schackmann; Irene L Wapnir; Robert W Carlson; Pei-Jen Chang; Joseph A Sparano; Bobbie Head; Lori J Goldstein; Barbara Haley; Shaker R Dakhil; Julia E Reid; Anne-Renee Hartman; Judith Manola; James M Ford
Journal:  J Clin Oncol       Date:  2015-04-06       Impact factor: 44.544

7.  Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.

Authors:  Angel Chao; Chyong-Huey Lai; Tzu-Hao Wang; Shih-Ming Jung; Yun-Shien Lee; Wei-Yang Chang; Lan-Yang Yang; Fei-Chun Ku; Huei-Jean Huang; An-Shine Chao; Chin-Jung Wang; Ting-Chang Chang; Ren-Chin Wu
Journal:  J Mol Med (Berl)       Date:  2018-05-03       Impact factor: 4.599

Review 8.  Tumour heterogeneity and metastasis at single-cell resolution.

Authors:  Devon A Lawson; Kai Kessenbrock; Ryan T Davis; Nicholas Pervolarakis; Zena Werb
Journal:  Nat Cell Biol       Date:  2018-11-26       Impact factor: 28.824

9.  Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.

Authors:  Melinda L Telli; Kirsten M Timms; Julia Reid; Bryan Hennessy; Gordon B Mills; Kristin C Jensen; Zoltan Szallasi; William T Barry; Eric P Winer; Nadine M Tung; Steven J Isakoff; Paula D Ryan; April Greene-Colozzi; Alexander Gutin; Zaina Sangale; Diana Iliev; Chris Neff; Victor Abkevich; Joshua T Jones; Jerry S Lanchbury; Anne-Renee Hartman; Judy E Garber; James M Ford; Daniel P Silver; Andrea L Richardson
Journal:  Clin Cancer Res       Date:  2016-03-08       Impact factor: 12.531

10.  BRCA 1/2 gene mutation and gastrointestinal stromal tumours: a potential association.

Authors:  Julie Waisbren; Regina Uthe; Kalliopi Siziopikou; Virginia Kaklamani
Journal:  BMJ Case Rep       Date:  2015-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.